APO Research
Talk to an analyst

APO RESEARCH · REPORT

Calcitonin Gene Related Peptide Type 1

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Calcitonin Gene Related Peptide Type 1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025181 pages

Choose your research edition.

Industry ResearchCalcitonin Gene Related Peptide Type 1 Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Calcitonin Gene Related Peptide Type 1 Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Calcitonin Gene Related Peptide Type 1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Calcitonin Gene Related Peptide Type 1 Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Calcitonin Gene Related Peptide Type 1 Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Calcitonin Gene Related Peptide Type 1 market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Calcitonin Gene Related Peptide Type 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Calcitonin Gene Related Peptide Type 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Calcitonin Gene Related Peptide Type 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Calcitonin Gene Related Peptide Type 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Calcitonin Gene Related Peptide Type 1 include Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, Amgen Inc, Vertex Pharmaceuticals Inc, Merck & Co Inc, Fortress Biotech Inc, Biohaven Pharmaceutical Holding Company Ltd and Allergan Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Calcitonin Gene Related Peptide Type 1 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Calcitonin Gene Related Peptide Type 1 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Calcitonin Gene Related Peptide Type 1 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Calcitonin Gene Related Peptide Type 1 market size, projected growth trends, production technologies, key applications, and end-use industries.

Calcitonin Gene Related Peptide Type 1 Segment by Company

Teva Pharmaceutical Industries Ltd

Eli Lilly and Company

Amgen Inc

Vertex Pharmaceuticals Inc

Merck & Co Inc

Fortress Biotech Inc

Biohaven Pharmaceutical Holding Company Ltd

Allergan Plc

Calcitonin Gene Related Peptide Type 1 Segment by Type

Erenumab

CGRP

AGN-241689

AFAP-3

Others

Calcitonin Gene Related Peptide Type 1 Segment by Application

Dental Pain

Cardiovascular

Metabolic Disorders

Others

Calcitonin Gene Related Peptide Type 1 Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Calcitonin Gene Related Peptide Type 1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Calcitonin Gene Related Peptide Type 1 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Calcitonin Gene Related Peptide Type 1.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Calcitonin Gene Related Peptide Type 1 market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Calcitonin Gene Related Peptide Type 1 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Calcitonin Gene Related Peptide Type 1 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Calcitonin Gene Related Peptide Type 1 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Calcitonin Gene Related Peptide Type 1 Industry Trends Table 2. Calcitonin Gene Related Peptide Type 1 Industry Drivers Table 3. Calcitonin Gene Related Peptide Type 1 Industry Opportunities and Challenges Table 4. Calcitonin Gene Related Peptide Type 1 Industry Restraints Table 5. Global Calcitonin Gene Related Peptide Type 1 Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Calcitonin Gene Related Peptide Type 1 Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Manufacturers Table 9. Global Calcitonin Gene Related Peptide Type 1 Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Calcitonin Gene Related Peptide Type 1 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Calcitonin Gene Related Peptide Type 1 Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Calcitonin Gene Related Peptide Type 1 Manufacturers, Product Type & Application Table 13. Global Calcitonin Gene Related Peptide Type 1 Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Calcitonin Gene Related Peptide Type 1 by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Erenumab Table 17. Major Manufacturers of CGRP Table 18. Major Manufacturers of AGN-241689 Table 19. Major Manufacturers of AFAP-3 Table 20. Major Manufacturers of Others Table 21. Global Calcitonin Gene Related Peptide Type 1 Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Calcitonin Gene Related Peptide Type 1 Sales by Type (2021-2026) & (k units) Table 23. Global Calcitonin Gene Related Peptide Type 1 Sales by Type (2027-2032) & (k units) Table 24. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Type (2021-2026) Table 25. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Type (2027-2032) Table 26. Global Calcitonin Gene Related Peptide Type 1 Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Calcitonin Gene Related Peptide Type 1 Revenue by Type (2021-2026) & (k units) Table 28. Global Calcitonin Gene Related Peptide Type 1 Revenue by Type (2027-2032) & (k units) Table 29. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Type (2021-2026) Table 30. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Dental Pain Table 32. Major Manufacturers of Cardiovascular Table 33. Major Manufacturers of Metabolic Disorders Table 34. Major Manufacturers of Others Table 35. Global Calcitonin Gene Related Peptide Type 1 Sales by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Calcitonin Gene Related Peptide Type 1 Sales by Application (2021-2026) & (k units) Table 37. Global Calcitonin Gene Related Peptide Type 1 Sales by Application (2027-2032) & (k units) Table 38. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Application (2021-2026) Table 39. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Application (2027-2032) Table 40. Global Calcitonin Gene Related Peptide Type 1 Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 41. Global Calcitonin Gene Related Peptide Type 1 Revenue by Application (2021-2026) & (k units) Table 42. Global Calcitonin Gene Related Peptide Type 1 Revenue by Application (2027-2032) & (k units) Table 43. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Application (2021-2026) Table 44. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Application (2027-2032) Table 45. Global Calcitonin Gene Related Peptide Type 1 Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Calcitonin Gene Related Peptide Type 1 Sales by Region (2021-2026) & (k units) Table 47. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Region (2021-2026) Table 48. Global Calcitonin Gene Related Peptide Type 1 Sales Forecasted by Region (2027-2032) & (k units) Table 49. Global Calcitonin Gene Related Peptide Type 1 Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Calcitonin Gene Related Peptide Type 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. North America Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2026) & (k units) Table 52. North America Calcitonin Gene Related Peptide Type 1 Sales by Country (2027-2032) & (k units) Table 53. Europe Calcitonin Gene Related Peptide Type 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Europe Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2026) & (k units) Table 55. Europe Calcitonin Gene Related Peptide Type 1 Sales by Country (2027-2032) & (k units) Table 56. Asia Pacific Calcitonin Gene Related Peptide Type 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Asia Pacific Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2026) & (k units) Table 58. Asia Pacific Calcitonin Gene Related Peptide Type 1 Sales by Country (2027-2032) & (k units) Table 59. South America, Middle East and Africa Calcitonin Gene Related Peptide Type 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 60. South America, Middle East and Africa Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2026) & (k units) Table 61. South America, Middle East and Africa Calcitonin Gene Related Peptide Type 1 Sales by Country (2027-2032) & (k units) Table 62. Global Calcitonin Gene Related Peptide Type 1 Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Calcitonin Gene Related Peptide Type 1 Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Calcitonin Gene Related Peptide Type 1 Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Region (2021-2026) Table 66. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Region (2027-2032) Table 67. Teva Pharmaceutical Industries Ltd Company Information Table 68. Teva Pharmaceutical Industries Ltd Business Overview Table 69. Teva Pharmaceutical Industries Ltd Calcitonin Gene Related Peptide Type 1 Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Teva Pharmaceutical Industries Ltd Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 71. Teva Pharmaceutical Industries Ltd Recent Development Table 72. Eli Lilly and Company Company Information Table 73. Eli Lilly and Company Business Overview Table 74. Eli Lilly and Company Calcitonin Gene Related Peptide Type 1 Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Eli Lilly and Company Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 76. Eli Lilly and Company Recent Development Table 77. Amgen Inc Company Information Table 78. Amgen Inc Business Overview Table 79. Amgen Inc Calcitonin Gene Related Peptide Type 1 Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Amgen Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 81. Amgen Inc Recent Development Table 82. Vertex Pharmaceuticals Inc Company Information Table 83. Vertex Pharmaceuticals Inc Business Overview Table 84. Vertex Pharmaceuticals Inc Calcitonin Gene Related Peptide Type 1 Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Vertex Pharmaceuticals Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 86. Vertex Pharmaceuticals Inc Recent Development Table 87. Merck & Co Inc Company Information Table 88. Merck & Co Inc Business Overview Table 89. Merck & Co Inc Calcitonin Gene Related Peptide Type 1 Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Merck & Co Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 91. Merck & Co Inc Recent Development Table 92. Fortress Biotech Inc Company Information Table 93. Fortress Biotech Inc Business Overview Table 94. Fortress Biotech Inc Calcitonin Gene Related Peptide Type 1 Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Fortress Biotech Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 96. Fortress Biotech Inc Recent Development Table 97. Biohaven Pharmaceutical Holding Company Ltd Company Information Table 98. Biohaven Pharmaceutical Holding Company Ltd Business Overview Table 99. Biohaven Pharmaceutical Holding Company Ltd Calcitonin Gene Related Peptide Type 1 Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Biohaven Pharmaceutical Holding Company Ltd Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 101. Biohaven Pharmaceutical Holding Company Ltd Recent Development Table 102. Allergan Plc Company Information Table 103. Allergan Plc Business Overview Table 104. Allergan Plc Calcitonin Gene Related Peptide Type 1 Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Allergan Plc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 106. Allergan Plc Recent Development Table 107. Key Raw Materials Table 108. Raw Materials Key Suppliers Table 109. Calcitonin Gene Related Peptide Type 1 Distributors List Table 110. Calcitonin Gene Related Peptide Type 1 Customers List Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Calcitonin Gene Related Peptide Type 1 Product Image Figure 2. Global Calcitonin Gene Related Peptide Type 1 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Calcitonin Gene Related Peptide Type 1 Market Size (2021-2032) & (US$ Million) Figure 4. Global Calcitonin Gene Related Peptide Type 1 Sales (2021-2032) & (k units) Figure 5. Global Calcitonin Gene Related Peptide Type 1 Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Calcitonin Gene Related Peptide Type 1 Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Erenumab Image Figure 9. CGRP Image Figure 10. AGN-241689 Image Figure 11. AFAP-3 Image Figure 12. Others Image Figure 13. Global Calcitonin Gene Related Peptide Type 1 Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Type (2021-2032) Figure 16. Global Calcitonin Gene Related Peptide Type 1 Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Type (2021-2032) Figure 19. Dental Pain Image Figure 20. Cardiovascular Image Figure 21. Metabolic Disorders Image Figure 22. Others Image Figure 23. Global Calcitonin Gene Related Peptide Type 1 Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Application (2021-2032) Figure 26. Global Calcitonin Gene Related Peptide Type 1 Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Application (2021-2032) Figure 29. North America Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 30. North America Calcitonin Gene Related Peptide Type 1 Sales Market Share by Country (2021-2032) Figure 31. U.S. Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 32. Canada Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 33. Mexico Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Calcitonin Gene Related Peptide Type 1 Sales Market Share by Country (2021-2032) Figure 36. Germany Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 37. France Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 38. U.K. Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 39. Italy Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 40. Netherlands Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Calcitonin Gene Related Peptide Type 1 Sales Market Share by Country (2021-2032) Figure 43. China Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 44. Japan Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 45. South Korea Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 46. Southeast Asia Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 47. India Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 48. Australia Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Calcitonin Gene Related Peptide Type 1 Sales Market Share by Country (2021-2032) Figure 51. Brazil Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 52. South Africa Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 53. Saudi Arabia Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 54. Turkey Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 55. Argentina Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 56. UAE Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 57. Egypt Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 58. Chile Calcitonin Gene Related Peptide Type 1 Sales and Growth Rate (2021-2032) & (k units) Figure 59. Global Calcitonin Gene Related Peptide Type 1 Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Calcitonin Gene Related Peptide Type 1 Revenue (2021-2032) & (US$ Million) Figure 62. North America Calcitonin Gene Related Peptide Type 1 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Calcitonin Gene Related Peptide Type 1 Revenue (2021-2032) & (US$ Million) Figure 64. Europe Calcitonin Gene Related Peptide Type 1 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Calcitonin Gene Related Peptide Type 1 Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Calcitonin Gene Related Peptide Type 1 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Calcitonin Gene Related Peptide Type 1 Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Calcitonin Gene Related Peptide Type 1 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Calcitonin Gene Related Peptide Type 1 Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Calcitonin Gene Related Peptide Type 1 Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Erenumab
  • CGRP
  • AGN-241689
  • AFAP-3
  • Others
Applications
  • Dental Pain
  • Cardiovascular
  • Metabolic Disorders
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Eli Lilly and Company
  • Amgen Inc
  • Vertex Pharmaceuticals Inc
  • Merck & Co Inc
  • Fortress Biotech Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • Allergan Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Calcitonin Gene Related Peptide Type 1 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Calcitonin Gene Related Peptide Type 1 Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Calcitonin Gene Related Peptide Type 1 Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Calcitonin Gene Related Peptide Type 1 Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Calcitonin Gene Related Peptide Type 1 Market Dynamics
  1. 2.1 Calcitonin Gene Related Peptide Type 1 Industry Trends
  2. 2.2 Calcitonin Gene Related Peptide Type 1 Industry Drivers
  3. 2.3 Calcitonin Gene Related Peptide Type 1 Industry Opportunities and Challenges
  4. 2.4 Calcitonin Gene Related Peptide Type 1 Industry Restraints
3 Calcitonin Gene Related Peptide Type 1 Market by Manufacturers
  1. 3.1 Global Calcitonin Gene Related Peptide Type 1 Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Calcitonin Gene Related Peptide Type 1 Sales by Manufacturers (2021-2026)
  3. 3.3 Global Calcitonin Gene Related Peptide Type 1 Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Calcitonin Gene Related Peptide Type 1 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Calcitonin Gene Related Peptide Type 1 Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Calcitonin Gene Related Peptide Type 1 Manufacturers, Product Type & Application
  7. 3.7 Global Calcitonin Gene Related Peptide Type 1 Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Calcitonin Gene Related Peptide Type 1 Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Calcitonin Gene Related Peptide Type 1 Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Calcitonin Gene Related Peptide Type 1 Tier 1, Tier 2, and Tier 3
4 Calcitonin Gene Related Peptide Type 1 Market by Type
  1. 4.1 Calcitonin Gene Related Peptide Type 1 Type Introduction
  2. 4.1.1 Erenumab
  3. 4.1.2 CGRP
  4. 4.1.3 AGN-241689
  5. 4.1.4 AFAP-3
  6. 4.1.5 Others
  7. 4.2 Global Calcitonin Gene Related Peptide Type 1 Sales by Type
  8. 4.2.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Calcitonin Gene Related Peptide Type 1 Sales by Type (2021-2032)
  10. 4.2.3 Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Type (2021-2032)
  11. 4.3 Global Calcitonin Gene Related Peptide Type 1 Revenue by Type
  12. 4.3.1 Global Calcitonin Gene Related Peptide Type 1 Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Calcitonin Gene Related Peptide Type 1 Revenue by Type (2021-2032)
  14. 4.3.3 Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Type (2021-2032)
5 Calcitonin Gene Related Peptide Type 1 Market by Application
  1. 5.1 Calcitonin Gene Related Peptide Type 1 Application Introduction
  2. 5.1.1 Dental Pain
  3. 5.1.2 Cardiovascular
  4. 5.1.3 Metabolic Disorders
  5. 5.1.4 Others
  6. 5.2 Global Calcitonin Gene Related Peptide Type 1 Sales by Application
  7. 5.2.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Calcitonin Gene Related Peptide Type 1 Sales by Application (2021-2032)
  9. 5.2.3 Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Application (2021-2032)
  10. 5.3 Global Calcitonin Gene Related Peptide Type 1 Revenue by Application
  11. 5.3.1 Global Calcitonin Gene Related Peptide Type 1 Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Calcitonin Gene Related Peptide Type 1 Revenue by Application (2021-2032)
  13. 5.3.3 Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Application (2021-2032)
6 Global Calcitonin Gene Related Peptide Type 1 Sales by Region
  1. 6.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Calcitonin Gene Related Peptide Type 1 Sales by Region (2021-2032)
  3. 6.2.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Region (2021-2026)
  4. 6.2.2 Global Calcitonin Gene Related Peptide Type 1 Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Calcitonin Gene Related Peptide Type 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Calcitonin Gene Related Peptide Type 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Calcitonin Gene Related Peptide Type 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Calcitonin Gene Related Peptide Type 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Calcitonin Gene Related Peptide Type 1 Revenue by Region
  1. 7.1 Global Calcitonin Gene Related Peptide Type 1 Revenue by Region
  2. 7.1.1 Global Calcitonin Gene Related Peptide Type 1 Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Calcitonin Gene Related Peptide Type 1 Revenue by Region (2021-2026)
  4. 7.1.3 Global Calcitonin Gene Related Peptide Type 1 Revenue by Region (2027-2032)
  5. 7.1.4 Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Calcitonin Gene Related Peptide Type 1 Revenue (2021-2032)
  8. 7.2.2 North America Calcitonin Gene Related Peptide Type 1 Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Calcitonin Gene Related Peptide Type 1 Revenue (2021-2032)
  11. 7.3.2 Europe Calcitonin Gene Related Peptide Type 1 Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Calcitonin Gene Related Peptide Type 1 Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Calcitonin Gene Related Peptide Type 1 Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Calcitonin Gene Related Peptide Type 1 Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Calcitonin Gene Related Peptide Type 1 Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd
  2. 8.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd Calcitonin Gene Related Peptide Type 1 Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd Calcitonin Gene Related Peptide Type 1 Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 8.2 Eli Lilly and Company
  8. 8.2.1 Eli Lilly and Company Company Information
  9. 8.2.2 Eli Lilly and Company Business Overview
  10. 8.2.3 Eli Lilly and Company Calcitonin Gene Related Peptide Type 1 Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly and Company Calcitonin Gene Related Peptide Type 1 Product Portfolio
  12. 8.2.5 Eli Lilly and Company Recent Developments
  13. 8.3 Amgen Inc
  14. 8.3.1 Amgen Inc Company Information
  15. 8.3.2 Amgen Inc Business Overview
  16. 8.3.3 Amgen Inc Calcitonin Gene Related Peptide Type 1 Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  18. 8.3.5 Amgen Inc Recent Developments
  19. 8.4 Vertex Pharmaceuticals Inc
  20. 8.4.1 Vertex Pharmaceuticals Inc Company Information
  21. 8.4.2 Vertex Pharmaceuticals Inc Business Overview
  22. 8.4.3 Vertex Pharmaceuticals Inc Calcitonin Gene Related Peptide Type 1 Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Vertex Pharmaceuticals Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  24. 8.4.5 Vertex Pharmaceuticals Inc Recent Developments
  25. 8.5 Merck & Co Inc
  26. 8.5.1 Merck & Co Inc Company Information
  27. 8.5.2 Merck & Co Inc Business Overview
  28. 8.5.3 Merck & Co Inc Calcitonin Gene Related Peptide Type 1 Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  30. 8.5.5 Merck & Co Inc Recent Developments
  31. 8.6 Fortress Biotech Inc
  32. 8.6.1 Fortress Biotech Inc Company Information
  33. 8.6.2 Fortress Biotech Inc Business Overview
  34. 8.6.3 Fortress Biotech Inc Calcitonin Gene Related Peptide Type 1 Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Fortress Biotech Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  36. 8.6.5 Fortress Biotech Inc Recent Developments
  37. 8.7 Biohaven Pharmaceutical Holding Company Ltd
  38. 8.7.1 Biohaven Pharmaceutical Holding Company Ltd Company Information
  39. 8.7.2 Biohaven Pharmaceutical Holding Company Ltd Business Overview
  40. 8.7.3 Biohaven Pharmaceutical Holding Company Ltd Calcitonin Gene Related Peptide Type 1 Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Biohaven Pharmaceutical Holding Company Ltd Calcitonin Gene Related Peptide Type 1 Product Portfolio
  42. 8.7.5 Biohaven Pharmaceutical Holding Company Ltd Recent Developments
  43. 8.8 Allergan Plc
  44. 8.8.1 Allergan Plc Company Information
  45. 8.8.2 Allergan Plc Business Overview
  46. 8.8.3 Allergan Plc Calcitonin Gene Related Peptide Type 1 Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Allergan Plc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  48. 8.8.5 Allergan Plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Calcitonin Gene Related Peptide Type 1 Value Chain Analysis
  2. 9.1.1 Calcitonin Gene Related Peptide Type 1 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Calcitonin Gene Related Peptide Type 1 Production Mode & Process
  6. 9.2 Calcitonin Gene Related Peptide Type 1 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Calcitonin Gene Related Peptide Type 1 Distributors
  9. 9.2.3 Calcitonin Gene Related Peptide Type 1 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst